Breaking News, Trials & Filings

NeuroBo Pharmaceuticals to Initiate Phase 3 Trial

Study will evaluate the efficacy of its lead drug, NB-01, in diabetic neuropathic pain, and is set to start in Q2 of this year

NeuroBo Pharmaceuticals announced its plans to initiate a Phase III trial to evaluate the efficacy of its lead drug, NB-01, in diabetic neuropathic pain in early Q2, 2019. The Company’s drug pipeline also includes an IND-ready therapeutic candidate for Alzheimer’s disease. These two candidates are based on extensive clinical and/or preclinical R&D originally conducted by Dong-A ST, a major Korean pharmaceutical company. “The planned initiation of our Phase III study for NB-01 marks a cruc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters